Current PD-L1 immunohistochemistry for non-small cell lung cancer.
作者信息
Scheel Andreas H, Schäfer Stephan C
机构信息
Institute of Pathology, University Hospital Cologne, Cologne, Germany.
出版信息
J Thorac Dis. 2018 Mar;10(3):1217-1219. doi: 10.21037/jtd.2018.02.38.
Abstract
摘要
相似文献
1
Current PD-L1 immunohistochemistry for non-small cell lung cancer.目前用于非小细胞肺癌的程序性死亡受体配体1免疫组织化学检测
J Thorac Dis. 2018 Mar;10(3):1217-1219. doi: 10.21037/jtd.2018.02.38.
2
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.免疫组织化学、mRNA 原位杂交检测 PD-L1 表达的一致性水平及其与肺癌预后的关系。
Hum Pathol. 2018 Dec;82:282-288. doi: 10.1016/j.humpath.2018.07.025. Epub 2018 Jul 31.
3
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.非小细胞肺癌中程序性死亡受体配体1（PD-L1）的表达：细胞学、小活检及手术切除标本的比较
Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.
4
Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.多中心研究：PD-L1 免疫组化作为预测非小细胞肺癌免疫治疗的一致性研究。
J Clin Pathol. 2020 Jul;73(7):423-430. doi: 10.1136/jclinpath-2019-205993. Epub 2019 Dec 10.
5
Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.程序性死亡配体 1 在非小细胞肺癌直接巴氏染色细胞学涂片上的表达：与细胞块和手术切除标本的比较。
Cancer Cytopathol. 2019 Jul;127(7):470-480. doi: 10.1002/cncy.22155. Epub 2019 Jun 27.
6
[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].[支气管活检中PD-L1状态免疫组化评估的问题及当前局限]
Bull Cancer. 2016 Apr;103(4):368-80. doi: 10.1016/j.bulcan.2016.01.014. Epub 2016 Feb 23.
7
[Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer].[非小细胞肺癌中PD-L1检测方法的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Jan 20;22(1):40-44. doi: 10.3779/j.issn.1009-3419.2019.01.08.
8
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.新型多重液滴数字 PCR 分析方法用于检测非小细胞肺癌活检标本中的 PD-L1 表达。
Lung Cancer. 2019 Aug;134:233-237. doi: 10.1016/j.lungcan.2019.06.029. Epub 2019 Jul 2.
9
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].[非小细胞肺癌的预测性程序性死亡受体 1 免疫组化：当前技术水平及德国首次协调研究经验]
Pathologe. 2016 Nov;37(6):557-567. doi: 10.1007/s00292-016-0189-1.
10
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.晚期非小细胞肺癌配对活检和液基细胞学样本中程序性死亡配体1的免疫表达情况
Cytopathology. 2018 Dec;29(6):550-557. doi: 10.1111/cyt.12605. Epub 2018 Jul 30.
引用本文的文献
1
Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.肠道微生物群分析：非小细胞肺癌免疫检查点阻断治疗生物标志物的新兴来源
Cancers (Basel). 2021 May 21;13(11):2514. doi: 10.3390/cancers13112514.
2
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.ERBB2 基因拷贝数增加揭示了具有高肿瘤浸润淋巴细胞密度和 PD-L1 表达的唾液腺癌亚组。
Head Neck Pathol. 2020 Dec;14(4):951-965. doi: 10.1007/s12105-020-01163-x. Epub 2020 Apr 29.
3
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.PD-1/PD-L1 免疫疗法在非小细胞肺癌中的临床研究进展及潜在联合治疗策略。
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419890020. doi: 10.1177/1534735419890020.
4
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.绘制用于免疫肿瘤治疗的程序性细胞死亡配体-1 预测性免疫组织化学检测中使用的抗体结合位点图谱。
Mod Pathol. 2020 Apr;33(4):518-530. doi: 10.1038/s41379-019-0372-z. Epub 2019 Sep 26.
5
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).程序性死亡配体 1（PD-L1）作为预测晚期非小细胞肺癌（NSCLC）患者接受派姆单抗治疗的生物标志物。
Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20.
6
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.SAMHD1 对低甲基化药物的选择性失活为 AML 的治疗分层提供了依据。
Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4.
7
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.使用不同抗体和平台检测非小细胞肺癌的 PD-L1：一项瑞士交叉验证研究。
Virchows Arch. 2019 Jul;475(1):67-76. doi: 10.1007/s00428-019-02582-0. Epub 2019 May 24.
8
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.抗 PD-1/PD-L1 治疗非小细胞肺癌：迈向个体化医学和联合策略。
J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018.
本文引用的文献
1
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.程序性死亡配体 1 免疫组织化学检测：非小细胞肺癌中分析检测方法及临床应用的综述。
J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20.
2
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤：一项多中心、随机、开放标签的 3 期研究（KEYNOTE-006）的最终总生存结果。
Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.
3
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
4
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
5
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
Zotero 插件